DoD Joint Warfighter Medical, Military Medical Research and Development Award

The summary for the DoD Joint Warfighter Medical, Military Medical Research and Development Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DoD Joint Warfighter Medical, Military Medical Research and Development Award: This MMRDA mechanism is intended to support a logical continuation of previously funded, prior year research or development efforts relevant to the above FY22 JWMRP Focus Areas with the highest potential to augment and accelerate medical product development and healthcare solutions for military Service Members, Veterans, their families, other MHS beneficiaries, and/or the American public. The USAMRDC will implement this research program through the awarding of assistance agreements (grants and cooperative agreements), research contracts, or Other Transaction Agreements (OTAs). All invited applicants must submit full applications in accordance with the procedures outlined in this funding opportunity announcement. Collaboration with DOD organizations is encouraged when this alliance would contribute to the success of the research effort, and any funds designated for DOD laboratories or activities should be identified in the application through submission of a “Suggested Collaborating DOD Military Facility Budget Format,” Attachment 15. Funding from this award mechanism may be used for a wide range of research projects spanning preclinical studies, translational and technology development, clinical studies (including correlative studies and initial safety and efficacy testing of promising drug and vaccine candidates, medical devices and technologies), and phase 1, phase 2, or phase 3 clinical trials.